Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boiron

Showing results (311-320 of 331) with videos related to

Pageof 34
Sort By:
Bone Marrow Transplantation|May 1, 1996
High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemiaF X Mahon, C Fabères, M Montastruc, et al.
Blood|December 3, 1998
Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alphaF X Mahon, C Fabères, S Pueyo, et al.
Bone Marrow Transplantation|July 12, 2005
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trialD Valteau-Couanet, C Faucher, A Aupérin, et al.
La Nouvelle Presse Medicale|October 5, 1974
[Initial therapy of Hodgkin's disease using polychemotherapy. Long-term results of 204 cases (1-8 year follow-up)]C Jacquillat, M Weil, G Auclerc, et al.
Bone Marrow Transplantation|November 25, 1998
Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experienceR M Lowenthal, C Fabères, G Marit, et al.
Leukemia|September 16, 1998
Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric studyG Marit, F Thiessard, C Faberes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myelomaG Marit, C Faberes, J L Pico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de MoelleD Blaise, M Kuentz, C Fortanier, et al.
Leukemia & Lymphoma|November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study GroupE Jourdan, J Reiffers, A M Stoppa, et al.
Bone Marrow Transplantation|May 11, 2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantationM Mohty, J M Boiron, G Damaj, et al.
Pageof 34

Showing results (311-320 of 331) with videos related to

Sort By:
Pageof 34
Bone Marrow Transplantation|May 1, 1996
High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemiaF X Mahon, C Fabères, M Montastruc, et al.
Blood|December 3, 1998
Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alphaF X Mahon, C Fabères, S Pueyo, et al.
Bone Marrow Transplantation|July 12, 2005
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trialD Valteau-Couanet, C Faucher, A Aupérin, et al.
La Nouvelle Presse Medicale|October 5, 1974
[Initial therapy of Hodgkin's disease using polychemotherapy. Long-term results of 204 cases (1-8 year follow-up)]C Jacquillat, M Weil, G Auclerc, et al.
Bone Marrow Transplantation|November 25, 1998
Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experienceR M Lowenthal, C Fabères, G Marit, et al.
Leukemia|September 16, 1998
Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric studyG Marit, F Thiessard, C Faberes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myelomaG Marit, C Faberes, J L Pico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de MoelleD Blaise, M Kuentz, C Fortanier, et al.
Leukemia & Lymphoma|November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study GroupE Jourdan, J Reiffers, A M Stoppa, et al.
Bone Marrow Transplantation|May 11, 2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantationM Mohty, J M Boiron, G Damaj, et al.
Pageof 34